



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/541,473	01/19/2006	Milind Moreshwar Gharpure	U 015837-4	8926
140	7590	06/27/2008	EXAMINER	
LADAS & PARRY LLP 26 WEST 61ST STREET NEW YORK, NY 10023			BERCH, MARK L	
ART UNIT	PAPER NUMBER			
	1624			
MAIL DATE	DELIVERY MODE			
06/27/2008	PAPER			

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/541,473	Applicant(s) GHARPURE ET AL.
	Examiner /Mark L. Berch/	Art Unit 1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-16 and 18-23 is/are pending in the application.
 - 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) Claim(s) ____ is/are allowed.
- 6) Claim(s) 1-16, 18-23 is/are rejected.
- 7) Claim(s) ____ is/are objected to.
- 8) Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO/SB/08) _____
 Paper No(s)/Mail Date 07/06/2009.
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date. _____.
- 5) Notice of Informal Patent Application
- 6) Other: _____

DETAILED ACTION

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim*** rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

1. Claim 1 contains a copying error, as the last 5 lines of original claim 1 were omitted.
2. As claim 1 is actually written, it does not obtain a pure material. One actually ends up with a neutralized aqueous solution, which cannot be pure because it contains the byproduct salt of the neutralization, e.g. Na methansulfonate.
3. The structure of cefpodoxime proxetil is misdrawn. There should be an isopropyl group at the right side, not an ethyl group.
4. In addition, in Formula (I), the oxo group is missing on the carbon attached to the 7-amino group.
5. The term "high purity" is indefinite. The term "pure" is indefinite. What level of purity is required by such language? 90%? 95%? 99%? 99.5%? 99.9%? 99.99%? Such terms of degree are indefinite when the specification contains no "explicit guidelines" to

distinguish from things which are not so, *Ex parte Oetiker*, 23 USPQ2d 1651, 1655 (1990) and *Ex parte Oetiker*, 23 USPQ2d 1641, and *Seattle Box Co. v. Industrial Crating & Packaging, Inc.* 221 USPQ 568, 574. There is no clear indication of what is the minimum level of purity needed to qualify for the claim.

6. The same is true of the phase “free of impurities”. How free?
7. The term “conforming to pharmacopoeial specification” is unclear. What does it mean?
8. Claim 3’s “first organic solvent” is unclear. The only place this exact term appears is in the second branch of claim 1. However, In the first branch, there is “an organic solvent” which is first mentioned two lines below the formula I, so it might refer to that as well.
9. The term “dipolar aprotic solvents” is indefinite in claim 16 because it has two possible meanings: 1) possessing a dipole moment and 2) having two (“di”) polar atoms. Thus, for example, diethyl ether would qualify under 1) but not 2). Carbon disulfide would qualify under 2) but not 1).
10. Claim 16 is confused. It says, “wherein the water-miscible organic solvent....” But claim 1 has no “water-miscible organic solvent”. Claim 3 actually has “water-immiscible organic solvent”. Further, the claim 16 list includes both types, e.g. lower alcohols (e.g. methanol), which are water-miscible organic solvents, and lower alkyl ketones (e.g. methyl ethyl ketone), which are water-immiscible organic solvents.

Claims 1-2, 9-15, 18-23 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The claims are not enabled as written. Claim 1 permits any "organic solvent" and any "co-solvent". Neither is required to be water immiscible, and unless one of these is, the separation cannot be done.

Claims 1-16, 18-23 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The process as written is incomplete and cannot therefore be considered enabled. According to the specification, the aqueous phase is actually extracted with ethyl acetate and cyclohexane both. See examples 4-6, and thus it appears that this is an essential part of the process.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to /Mark L. Berch/ whose telephone number is 571-272-0663. The examiner can normally be reached on M-F 7:15 - 3:45.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on (571)272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Mark L. Berch/
Primary Examiner
Art Unit 1624

6/29/2008